<DOC>
	<DOCNO>NCT00491829</DOCNO>
	<brief_summary>To establish efficacy Flibanserin 50 Milligrams Daily 100 Milligrams Daily 6-month treatment , v placebo Hypoactive Sexual Desire Disorder premenopausal European woman . To evaluate safety tolerability flibanserin patient .</brief_summary>
	<brief_title>Flibanserin Versus Placebo Premenopausal Women With HSDD</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<criteria>1 . Women 18 year age old Screen Visit . 2 . Premenopausal woman per Stages Reproductive Aging Workshop ( STRAW ) criteria primary diagnosis HSDD , generalize acquire type , accord DSM IVTR criterion . The current episode must least 24 week duration Baseline Visit . Secondary Female Sexual Arousal Disorder and/or Female Orgasmic Disorder allow . This inclusion criterion meet HSDD commence prior Female Sexual Arousal Disorder and/or Female Orgasmic Disorder HSDD importance patient , investigator judgement 3 . A score 15 high Female Sexual Distress ScaleRevised ( FSDSR ) © ( R041068 ) Screen Visit . 4 . Item Number Two Sexual Interest Desire Inventory Female© ( SIDIF© ) must rat `` 0 '' `` 1 '' Screen Visit 5 . Patients must willing try sexual activity ( e.g. , act involve direct genital stimulation ) least monthly . 6 . Patients must willing able use eDiary daily basis ( e.g. , access work land line wireless telephone daily data transmission ) . 7 . At Baseline Visit , patient must comply eDiary use adequately , miss entry five less day 28day Screen period . 8 . Patients must stable , monogamous , heterosexual relationship secure communicative , least 1 year prior Screen Visit . The relationship partner sexually functional , psychologically physically , partner expect physically present ( i.e. , available sexual activity time 24 hour day ) least 50 % month 4week Screen period 24week efficacy period trial . 1 . Patients take medication note Appendix 10.6.1 , Part I List prohibited medication , within 30 day Screen Visit ; medication prohibit throughout participation study . 2 . Patients whose sexual function affect ( enhanced worsen ) investigator opinion medication within 30 day Screen Visit anytime prior Baseline Visit . This must determine investigator judgement perform detailed review patient sexual history concomitant therapy . 3 . Patients history drug dependence abuse ( include alcohol , define DSM IVTR opinion investigator ) within past 1 year 4 . Patients meet DSM IVTR criterion Sexual Aversion Disorder , SubstanceInduced Sexual Dysfunction , Dyspareunia ( cause inadequate foreplay stimulation alleviate lubricant ) , Vaginismus , Gender Identity Disorder , Paraphilia , Sexual Dysfunction Due General Medical Condition . 5 . Patients indicate sexual partner organic psychosexual dysfunction could interfere patient response treatment . 6 . Patients enter perimenopause stage ( menopausal transition ) post menopause stage [ i.e. , hysterectomy ( without bilateral oophorectomy ) , bilateral oophorectomy , endometrial ablation ( type ) , chemical induce ( e.g. , chemotherapy ) ] accord STRAW criterion . 7 . Patients history MDD within 6 month prior Screen Visit score 14 Beck Depression Inventory© II , history suicide attempt accord Beck Scale Suicide Ideation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>